当前位置： SCI文献检索 > BREAST CANCER RESEARCH期刊下所有文献 > Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Abstract：

:Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.

journal_name

Breast Cancer Res

journal_title

Breast cancer research : BCR

authors

Rossi L,Biagioni C,McCartney A,Migliaccio I,Curigliano G,Sanna G,Moretti E,Minisini AM,Cinieri S,Tondini C,Arpino G,Bernardo A,Martignetti A,Risi E,Pestrin M,Boni L,Benelli M,Biganzoli L,Di Leo A,Malorni L

doi

10.1186/s13058-019-1149-5

subject

Has Abstract

pub_date

2019-05-29 00:00:00

pages

71

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-019-1149-5

journal_volume

21

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH文献大全
  • Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

    abstract：INTRODUCTION:Triple-negative breast cancer does not express estrogen and progesterone receptors, and no overexpression/amplification of the HER2-neu gene occurs. Therefore, this subtype of breast cancer lacks the benefits of specific therapies that target these receptors. Today chemotherapy is the only systematic thera...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2606

    authors： Gründker C,Föst C,Fister S,Nolte N,Günthert AR,Emons G

    更新日期：2010-01-01 00:00:00

  • Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

    abstract：INTRODUCTION:Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2903

    authors： Kodera Y,Katanasaka Y,Kitamura Y,Tsuda H,Nishio K,Tamura T,Koizumi F

    更新日期：2011-06-21 00:00:00

  • Prognostic stromal gene signatures in breast cancer.

    abstract：INTRODUCTION:Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several different cell types. This study was designed to obtain more refined expres...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0530-2

    authors： Winslow S,Leandersson K,Edsjö A,Larsson C

    更新日期：2015-02-21 00:00:00

  • The effect of psychosocial factors on breast cancer outcome: a systematic review.

    abstract：INTRODUCTION:We sought to review the available evidence regarding the effect of psychosocial factors on the survival of breast cancer patients. METHODS:We systematically searched the PubMed and PsycINFO databases to identify relevant studies. RESULTS:We identified 31 studies examining the association of various psych...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,meta分析

    doi：10.1186/bcr1744

    authors： Falagas ME,Zarkadoulia EA,Ioannidou EN,Peppas G,Christodoulou C,Rafailidis PI

    更新日期：2007-01-01 00:00:00

  • Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.

    abstract：INTRODUCTION:Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appears to be required for restoration of proliferation in secondary tumors. We studied the interplay b...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3580

    authors： Hugo HJ,Pereira L,Suryadinata R,Drabsch Y,Gonda TJ,Gunasinghe NP,Pinto C,Soo ET,van Denderen BJ,Hill P,Ramsay RG,Sarcevic B,Newgreen DF,Thompson EW

    更新日期：2013-11-27 00:00:00

  • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

    abstract：BACKGROUND:We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423 as potential biomarkers for response to SERM therapy. The ZNF423rs9940645 SNP,...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-017-0890-x

    authors： Qin S,Ingle JN,Liu M,Yu J,Wickerham DL,Kubo M,Weinshilboum RM,Wang L

    更新日期：2017-08-18 00:00:00

  • In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.

    abstract：INTRODUCTION:Current approaches to inhibit oestrogen receptor-alpha (ERα) are focused on targeting its hormone-binding pocket and have limitations. Thus, we propose that inhibitors that bind to a coactivator-binding pocket on ERα, called activation function 2 (AF2), might overcome some of these limitations. METHODS:In...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0529-8

    authors： Singh K,Munuganti RS,Leblanc E,Lin YL,Leung E,Lallous N,Butler M,Cherkasov A,Rennie PS

    更新日期：2015-02-25 00:00:00

  • A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

    abstract：INTRODUCTION:Estrogen receptor-alpha (ER-alpha) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-beta) in various breast cancer risk groups treated with different therapeutic regimens is ava...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2139

    authors： Novelli F,Milella M,Melucci E,Di Benedetto A,Sperduti I,Perrone-Donnorso R,Perracchio L,Venturo I,Nisticò C,Fabi A,Buglioni S,Natali PG,Mottolese M

    更新日期：2008-01-01 00:00:00

  • Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.

    abstract：INTRODUCTION:MBD2, the gene encoding methyl-CpG-binding domain (MBD)2, is a major methylation related gene and functions as a transcriptional repressor that can specifically bind to the methylated regions of other genes. MBD2 may also mediate gene activation because of its potential DNA demethylase activity. The presen...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1283

    authors： Zhu Y,Brown HN,Zhang Y,Holford TR,Zheng T

    更新日期：2005-01-01 00:00:00

  • Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

    abstract：INTRODUCTION:Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3629

    authors： Singel SM,Batten K,Cornelius C,Jia G,Fasciani G,Barron SL,Wright WE,Shay JW

    更新日期：2014-03-19 00:00:00

  • Not all false positive diagnoses are equal: On the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography / digital tomosynthesis screening.

    abstract：BACKGROUND:Breast magnetic resonance imaging (MRI) has been reported to frequently result in false-positive diagnoses, limiting its positive predictive value (PPV). However, for PPV calculation, all nonmalignant tissue changes are equally considered false-positive, although the respective prognostic importance, and thu...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-018-0937-7

    authors： Kuhl CK,Keulers A,Strobel K,Schneider H,Gaisa N,Schrading S

    更新日期：2018-02-09 00:00:00

  • Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis!

    abstract：:The transition from pregnancy to lactation is a critical event in the survival of the newborn since all the nutrient requirements of the infant are provided by milk. While milk contains numerous components, including proteins, that aid in maintaining the health of the infant, lactose and milk fat represent the critica...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr1653

    authors： Anderson SM,Rudolph MC,McManaman JL,Neville MC

    更新日期：2007-01-01 00:00:00

  • Targeting bone metastases starting from the preneoplastic niche: home sweet home.

    abstract：:The metastatic process is a multistep coordinated event with a high degree of efficiency. Specific subpopulations of cancer stem cells, with tumor-initiating and migratory capacity, can selectively migrate towards sites that are able to promote survival and/or proliferation of metastatic tumor cells through a microenv...

    journal_title：Breast cancer research : BCR

    pub_type： 社论,评审

    doi：10.1186/bcr2911

    authors： Santini D,Vincenzi B,Pantano F,Tonini G,Bertoldo F

    更新日期：2011-08-16 00:00:00

  • Efficient treatment of breast cancer xenografts with multifunctionalized iron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery.

    abstract：INTRODUCTION:Tumor cells can effectively be killed by heat, e.g. by using magnetic hyperthermia. The main challenge in the field, however, is the generation of therapeutic temperatures selectively in the whole tumor region. We aimed to improve magnetic hyperthermia of breast cancer by using innovative nanoparticles whi...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-015-0576-1

    authors： Kossatz S,Grandke J,Couleaud P,Latorre A,Aires A,Crosbie-Staunton K,Ludwig R,Dähring H,Ettelt V,Lazaro-Carrillo A,Calero M,Sader M,Courty J,Volkov Y,Prina-Mello A,Villanueva A,Somoza Á,Cortajarena AL,Miranda R,Hilge

    更新日期：2015-05-13 00:00:00

  • Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis.

    abstract：INTRODUCTION:Aberrant microenvironment and endoplasmic reticulum (ER) stress are associated with solid-tumor progression. Stress proteins, like heat shock proteins and glucose-regulated proteins, are frequently overexpressed in human tumors. It has been reported that derlin-1 is involved in ER stress response. In vitro...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1849

    authors： Wang J,Hua H,Ran Y,Zhang H,Liu W,Yang Z,Jiang Y

    更新日期：2008-01-01 00:00:00

  • Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negati

    abstract：INTRODUCTION:Natural herbal compounds with novel actions different from existing breast cancer (BCa) treatment modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-O-galloyl-β-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through in...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2634

    authors： Chai Y,Lee HJ,Shaik AA,Nkhata K,Xing C,Zhang J,Jeong SJ,Kim SH,Lu J

    更新日期：2010-01-01 00:00:00

  • Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.

    abstract：BACKGROUND:The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in cases of European, African, and Latin American ancestry. METHODS:BC mutation carrier cases from...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01341-3

    authors： Tuazon AMA,Lott P,Bohórquez M,Benavides J,Ramirez C,Criollo A,Estrada-Florez A,Mateus G,Velez A,Carmona J,Olaya J,Garcia E,Polanco-Echeverry G,Stultz J,Alvarez C,Tapia T,Ashton-Prolla P,Brazilian Familial Cancer Network

    更新日期：2020-10-21 00:00:00

  • Familial risks of breast cancer.

    abstract：:A recent analysis by the Collaborative Group on Hormonal Factors in Breast Cancer has provided the most precise quantification to date of the familial risks of breast cancer. The familial relative risks are shown to decrease from more than fivefold in women younger than age 40 years with a first-degree relative aged y...

    journal_title：Breast cancer research : BCR

    pub_type： 社论

    doi：10.1186/bcr448

    authors： Easton DF

    更新日期：2002-01-01 00:00:00

  • Vitamin D receptor expression in invasive breast tumors and breast cancer survival.

    abstract：BACKGROUND:Vitamin D has been suggested to prevent and improve the prognosis of several cancers, including breast cancer. We have previously shown a U-shaped association between pre-diagnostic serum levels of vitamin D and risk of breast cancer-related death, with poor survival in patients with the lowest and the highe...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-019-1169-1

    authors： Huss L,Butt ST,Borgquist S,Elebro K,Sandsveden M,Rosendahl A,Manjer J

    更新日期：2019-07-29 00:00:00

  • Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.

    abstract：INTRODUCTION:Mammary stem cells are bipotential and suggested to be the origin of breast cancer development, but are elusive and vaguely characterized. Breast tumors can be divided into subgroups, each one requiring specific treatment. To determine a possible association between mammary stem cells and breast cancer, a ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2256

    authors： Williams C,Helguero L,Edvardsson K,Haldosén LA,Gustafsson JA

    更新日期：2009-01-01 00:00:00

  • Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.

    abstract：INTRODUCTION:Although aberrant tyrosine kinase signalling characterises particular breast cancer subtypes, a global analysis of tyrosine phosphorylation in mouse models of breast cancer has not been undertaken to date. This may identify conserved oncogenic pathways and potential therapeutic targets. METHODS:We applied...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-014-0437-3

    authors： Ali NA,Wu J,Hochgräfe F,Chan H,Nair R,Ye S,Zhang L,Lyons RJ,Pinese M,Lee HC,Armstrong N,Ormandy CJ,Clark SJ,Swarbrick A,Daly RJ

    更新日期：2014-09-09 00:00:00

  • Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry.

    abstract：:Immunohistochemistry is the most common method for companion diagnostic testing in breast cancer. The readings for estrogen receptor, progesterone receptor, and Her2 directly affect prescription of critical therapies. However, immunohistochemistry is highly sensitive to innumerable pre-analytic variables that result i...

    journal_title：Breast cancer research : BCR

    pub_type： 社论

    doi：10.1186/bcr2782

    authors： Siddiqui S,Rimm DL

    更新日期：2010-01-01 00:00:00

  • CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress.

    abstract：BACKGROUND:CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast canc...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/s13058-020-01361-z

    authors： Balcioglu O,Heinz RE,Freeman DW,Gates BL,Hagos BM,Booker E,Mirzaei Mehrabad E,Diesen HT,Bhakta K,Ranganathan S,Kachi M,Leblanc M,Gray PC,Spike BT

    更新日期：2020-11-13 00:00:00

  • Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.

    abstract：INTRODUCTION:Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a significant proportion of breast cancers. While clinically effective therapies targeting HER2 such as mAbs and tyrosine kinase inhibitors exist, tumors overexpressing HER2 eventually progress despite treatment. Thus, abrogation of ...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr3204

    authors： Ren XR,Wei J,Lei G,Wang J,Lu J,Xia W,Spector N,Barak LS,Clay TM,Osada T,Hamilton E,Blackwell K,Hobeika AC,Morse MA,Lyerly HK,Chen W

    更新日期：2012-06-07 00:00:00

  • Update on the use of aromatase inhibitors in early-stage breast cancer.

    abstract：:Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publicat...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2410

    authors： Kesisis G,Makris A,Miles D

    更新日期：2009-01-01 00:00:00

  • Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

    abstract：:Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr42

    authors： Kretzschmar M

    更新日期：2000-01-01 00:00:00

  • XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study.

    abstract：INTRODUCTION:It has been suggested that individuals with reduced DNA repair capacities might have increased susceptibility to environmentally induced cancer. In this study, we evaluated if polymorphisms in DNA repair genes XRCC1 (Arg280His, Arg399Gln) and XPD (Lys751Gln) modify individual breast cancer risk, with empha...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr1333

    authors： Metsola K,Kataja V,Sillanpää P,Siivola P,Heikinheimo L,Eskelinen M,Kosma VM,Uusitupa M,Hirvonen A

    更新日期：2005-01-01 00:00:00

  • Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

    abstract：INTRODUCTION:Breast tumor kinase (Brk/protein tyrosine kinase 6 (PTK6)) is a nonreceptor, soluble tyrosine kinase overexpressed in the majority of breast tumors. Previous work has placed Brk downstream of epidermal growth factor receptor (ErbB) activation and upstream of extracellular signal-regulated kinase 5 (ERK5) a...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章

    doi：10.1186/bcr2622

    authors： Castro NE,Lange CA

    更新日期：2010-01-01 00:00:00

  • On the role of tyrosine phosphatases as negative regulators of STAT signaling in breast cancers: new findings and future perspectives.

    abstract：:The increasing importance of signal transducer and activator of transcription 3 (STAT3) expression in human cancers has led several laboratories to examine in detail the expression of one of its major negative regulators in oncogenesis--the T-cell protein tyrosine phosphatase, nonreceptor type 2 (PTPN2). A recent pape...

    journal_title：Breast cancer research : BCR

    pub_type： 评论,杂志文章,评审

    doi：10.1186/bcr3437

    authors： Tremblay ML

    更新日期：2013-07-31 00:00:00

  • Breast cancer prognostic classification in the molecular era: the role of histological grade.

    abstract：:Breast cancer is a heterogeneous disease with varied morphological appearances, molecular features, behavior, and response to therapy. Current routine clinical management of breast cancer relies on the availability of robust clinical and pathological prognostic and predictive factors to support clinical and patient de...

    journal_title：Breast cancer research : BCR

    pub_type： 杂志文章,评审

    doi：10.1186/bcr2607

    authors： Rakha EA,Reis-Filho JS,Baehner F,Dabbs DJ,Decker T,Eusebi V,Fox SB,Ichihara S,Jacquemier J,Lakhani SR,Palacios J,Richardson AL,Schnitt SJ,Schmitt FC,Tan PH,Tse GM,Badve S,Ellis IO

    更新日期：2010-01-01 00:00:00